Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Bone loss due to aromatase inhibitors in breast cancer treatment identified
October 6th, 2005
Bone loss due to the use of aromatase inhibitors in breast cancer treatment was identified an adverse outcome in postmenopausal women. "The increasing use of systemic adjuvant therapies has considerably improved the prognosis from early breast cancer. However, some of these therapies affect bone metabolism, resulting in osteoporosis," scientists in England report. "Aromatase inhibitors lower circulating estrogen levels to almost unrecordable levels in postmenopausal women, predisposing them to bone loss with an increase in fracture risk," wrote Lester and Coleman in the British Journal of Cancer. "Ongoing clinical trials are favoring the use...
Source: Women's Health Weekly (2005-10-06)
|
